Cerevel Therapeutics Hldg (NASDAQ:CERE) just reported results for the second quarter of 2024.
- Cerevel Therapeutics Hldg reported earnings per share of -73 cents. This was below the analyst estimate for EPS of -61 cents.
- The company did not report any revenue for the quarter.